News from IAS 2011

The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) took place in Rome, Italy, 17-20th July, with more than 5000 delegates.

As the official online partner for scientific reporting, NAM published six free email bulletins, with original news reporting and links to abstracts.

The conference included an interesting and diverse collection of presentations and sessions, covering a broad range of subjects in the HIV field, including new treatment, prevention and practice research.

This year’s conference had a major focus on treatment as prevention and on the use of antiretrovirals as pre-exposure prophylaxis (PrEP).

All our news reports from the conference are listed here, for the summary bulletins in English, French, Spanish, Portuguese or Russian, visit our conference bulletin page.

aidsmap news from IAS 2011

Gay men’s PrEP study final results: near 90% efficacy in men who took drug, but adherence even lower than thought

A completed series of investigations into the iPrEx study of tenofovir/FTC(Truvada) as pre-exposure prophylaxis (PrEP) has found that the drug was 92% efficacious in preventing HIV infection

Published
22 July 2011
By
Gus Cairns
New NNRTI lersivirine matches efavirenz in phase 2 study

Lersivirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), lowered HIV viral load about as well as efavirenz (Sustiva, Stocrin) for people starting antiretroviral therapy for the first time, researchers

Published
22 July 2011
By
Liz Highleyman
HIV vaccine technologists edge nearer to effective designs

A vaccine symposium held at the sixth International AIDS Society conference (IAS 2011) in Rome heard how designers are slowly developing HIV vaccines designed to overcome problems

Published
22 July 2011
By
Gus Cairns
Hormonal contraceptive use increases women’s risk of acquiring and transmitting HIV

A two-year, seven-country study has concluded that women using hormonal contraceptives, particularly injectable forms, are at a greater risk both of acquiring HIV themselves and of passing

Published
21 July 2011
By
Roger Pebody
Task-shifting of HIV care to nurses: successes, but problems to watch out for

“A nurse-led service can deliver ART care as effectively as a doctor-driven one, and even improves quality of care, but this pragmatic trial did not result in

Published
21 July 2011
By
Theo Smart
Once-daily elvitegravir matches raltegravir

The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well tolerated overall, according to data presented at

Published
21 July 2011
By
Liz Highleyman
HIV treatment in primary infection: 48 week course modestly delays CD4 drop

A 48-week course of antiretroviral treatment started within six months of becoming infected modestly delays the need for lifelong treatment, reported Dr Sarah Fidler of Imperial College,

Published
20 July 2011
By
Keith Alcorn
The roll-out of male circumcision: reduction in HIV prevalence, condom use maintained

The ongoing roll-out of male circumcision in Orange Farm, South Africa, has succeeded in bringing the proportion of men who are circumcised from 16 to 49% in

Published
20 July 2011
By
Roger Pebody
Cognitive impairment still common but ART reduces risk

Cognitive impairment remains common amongst people with HIV and is linked to more severe immune deficiency and absence of treatment, researchers reported at the International AIDS Society Conference

Published
20 July 2011
By
Liz Highleyman
From 'what if' to 'what now': implementing the new prevention technologies

Two consecutive sessions at the sixth International AIDS Society conference (IAS 2011) in Rome yesterday were devoted, now we have convincing scientific data on the benefits of

Published
20 July 2011
By
Gus Cairns
← Prev1234Next →

Coverage of the conference from CCO

Clinical Care Options (CCO) is the other official online partner of the conference. It will be providing audio highlights, capsule summaries and downloadable slidesets and we will link to their coverage in our news and bulletins, so you can have the fullest picture of the conference.

"Ending the epidemic is scientifically doable"

From 'what if' to 'what now': implementing the new prevention technologies.

Read this news story >

Treatment is prevention

HPTN 052 study shows 96% reduction in transmission when HIV-positive partner starts treatment early.

Read this news story >

Hormonal contraception and HIV

Hormonal contraceptive use increases women’s risk of acquiring and transmitting HIV.

Read this news story >

PrEP works for women too

Pre-exposure prophylaxis does work for women, two studies find.

Read this news story >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.